Nonetheless, in the ATHOS-3 trial, the proportion of serious ischemic adverse effects (digital, gut, myocardial) and cardiac arrhythmias were similar in patients receiving angiotensin II or placebo (37). This evidence concerns the gene AGT and cardiac arrhythmia.